Vivoryon Therapeutics' Phase 2b study of varoglutamstat for early Alzheimer's failed to improve cognition and function.
Vivoryon Therapeutics' Phase 2b VIVIAD study of varoglutamstat, an investigational oral glutaminyl cyclase (QPCT) inhibitor for early Alzheimer's disease, failed to meet primary and key secondary endpoints, showing no statistically significant difference in cognition and function. The drug was well-tolerated with low discontinuation rates and no symptomatic ARIAs. Vivoryon is analyzing additional endpoints and patient cohorts.
March 04, 2024
5 Articles